- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04603924
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
December 6, 2023 updated by: NeuroBo Pharmaceuticals Inc.
A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
Study Overview
Detailed Description
This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe hospitalized COVID-19 patients compared to placebo.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andrew Bartynski
- Phone Number: 1 650-263-1270
- Email: andrew@neurobopharma.com
Study Locations
-
-
Alabama
-
Sheffield, Alabama, United States, 35660
- Helen Keller Hospital
-
-
California
-
Irvine, California, United States, 92697
- University of California, Irvine
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist Health Research Institute
-
Tampa, Florida, United States, 33613
- AdventHealth Tampa
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri Health Care
-
-
North Carolina
-
Fayetteville, North Carolina, United States, 28303
- Caroline Institute for Clinical Research
-
-
Texas
-
Houston, Texas, United States, 77024
- Memorial Hermann Memorial City Medical Center
-
-
Washington
-
Everett, Washington, United States, 92801
- Providence Regional Medical Center Everett
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Provide written informed consent prior to performing study procedures
- Hospitalized.
- Male or female ≥18 years of age
- Positive for severe acute respiratory syndrome coronavirus 2
- Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more significant lower respiratory tract symptoms, including shortness of breath
- At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air oxygen saturation (SpO2) <98%, requirement for supplemental oxygen, heart rate (HR) ≥90 beats per minute, or temperature >38.3°C
- Women of childbearing potential must agree to abstinent or use at least 1 form of contraception not including hormonal contraception from the day of screening through Day 30
Key Exclusion Criteria:
- Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours)
- Patient is not anticipated to survive >48 hours OR is under palliative care
Evidence of critical illness, defined by at least 1 of the following:
Respiratory failure requiring at least 1 of the following:
- Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula
- Noninvasive positive pressure ventilation (NIPVV), OR
- Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure
- Shock (defined by systolic blood pressure (BP) <90 mm Hg, or diastolic blood pressure (BP) <60 mm Hg or requiring vasopressors), OR
- Multi-organ dysfunction/failure
- Severe central nervous system (CNS) conditions
- Chronic kidney disease requiring dialysis
- Known allergy to the study drug or salicylate containing medications.
- Suspected and/or confirmed pregnancy or breastfeeding
- Current or planned participation in any other clinical trial of a treatment being developed under a US investigational new drug (IND) or emergency use authorization (EUA).
- Patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease conditions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ANA001
Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal.
If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
|
Niclosamide is an antihelmintic with in-vitro antiviral activity
Other Names:
|
Placebo Comparator: Matching Placebo
Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
|
Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2)
Time Frame: Randomization to Day 28
|
Incidence of treatment emergent adverse events (TEAE's)
|
Randomization to Day 28
|
Efficacy as measured by median time to hospital discharge (Part 2)
Time Frame: Randomization to Day 60
|
Median time to hospital discharge
|
Randomization to Day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy as measured by median time to hospital discharge (Part 1)
Time Frame: Randomization to Day 60
|
Median time to hospital discharge
|
Randomization to Day 60
|
Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1)
Time Frame: Day 1, 2, 3 or 4
|
Plasma concentrations of ANA001
|
Day 1, 2, 3 or 4
|
Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2)
Time Frame: Day 15
|
Mean change from baseline in National Early Warning Score (NEWS 2) score
|
Day 15
|
Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2)
Time Frame: Within 15 days after enrollment
|
Mean number of days on rescue therapy
|
Within 15 days after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Doug Rank, MD, NeuroBo Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 7, 2020
Primary Completion (Actual)
February 16, 2022
Study Completion (Actual)
February 16, 2022
Study Registration Dates
First Submitted
October 20, 2020
First Submitted That Met QC Criteria
October 23, 2020
First Posted (Actual)
October 27, 2020
Study Record Updates
Last Update Posted (Actual)
December 8, 2023
Last Update Submitted That Met QC Criteria
December 6, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
- Infection
- Immunomodulator
- ARDS
- anti-inflammatory
- Acute Respiratory Distress Syndrome
- Virus
- Antiviral
- Acute Respiratory Distress Syndrome (ARDS)
- Viral
- bronchodilator
- Niclosamide
- Corona Virus Disease (COVID-19)
- Oral Niclosamide
- Cytokine dysregulation
- anthelmintic
- antineoplastic
- ANA001
- Moderate COVID-19
- Hospitalized COVID-19
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Anti-Infective Agents
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Niclosamide
Other Study ID Numbers
- ANA001-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Niclosamide
-
University of BaghdadRecruitingCovid-19 | SARS PneumoniaIraq
-
TFF Pharmaceuticals, Inc.Completed
-
Imuneks Farma ilac San. Tic. A.S.Unknown
-
Charité Research Organisation GmbHBayerTerminated
-
Yonsei UniversityRecruiting
-
First Wave Bio, Inc.TerminatedUlcerative Colitis | Ulcerative Proctitis | Ulcerative ProctosigmoiditisItaly
-
Charite University, Berlin, GermanyCenter for Molecular MedicineUnknown
-
National Institute of Allergy and Infectious Diseases...Terminated